Skip to content

US · TRAX · BIOTECHNOLOGY

First Tracks Biotherapeutics Inc (TRAX) intrinsic value and stock valuation

$41.64as of 2026-11-21 · Mkt cap 1.58B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

First Tracks Biotherapeutics Inc DCF and intrinsic value

InvestorsCraft values TRAX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TRAX’s statements →

Healthcare · Biotechnology San Diego, CA 92121 firsttracksbio.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$0.00
20232025
Net income
-$-166.09M
20232025
Free cash flow
-$-143.01M
20232025
Total equity
$287.5M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$0.00$0.00$0.00
Operating income-$-179.01M-$-181.1M-$-118.46M
Net income-$-166.09M-$-163.71M-$-106.15M
EPSd——-$-3.05M
Operating cash flow-$-142.93M-$-125.81M-$-93M
Capital expenditure-$-90K-$-360K-$-810K
Free cash flow-$-143.01M-$-126.16M-$-93.81M
Total assets$330.6M$441.9M$444.1M
Total debt$14.1M$16M$17.8M
Net debt-$-224.08M-$-107.04M-$-18.15M
Total equity$287.5M$391.6M$409.9M
Cash and short-term investments$311.6M$385.4M$390.9M
Income statement
202520242023
Revenue$0.00$0.00$0.00
Cost of revenue$139.6M$152.3M$0.00
Gross profit-$-139.61M-$-152.34M$0.00
Research and development expenses$139.6M$152.3M$97.6M
Selling, general and administrative expenses$39.4M$28.8M$20.9M
Other expenses-$-139.61M-$-152.34M$0.00
Operating expenses$39.4M$28.8M$118.5M
Cost and expenses$179M$181.1M$118.5M
Interest income$12.9M$17.4M$12.3M
Interest expense$0.00$0.00$0.00
Depreciation and amortization$560K$2.4M$2.38M
Ebitda-$-178.45M-$-178.7M-$-116.08M
Operating income-$-179.01M-$-181.1M-$-118.46M
Total other income/expenses, net$12.9M$17.4M$12.3M
Income before tax-$-166.09M-$-163.71M-$-106.15M
Income tax expense$0.00$0.00$0.00
Net income-$-166.09M-$-163.71M-$-106.15M
Weighted average shares outstanding$0.00$0.00$34.8M
Weighted average diluted shares outstanding$0.00$0.00$34.8M
Balance sheet
202520242023
Cash and short-term investments$311.6M$385.4M$390.9M
Net receivables$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Total current assets$316.4M$389.9M$398.6M
Property, plant and equipment, net$13.9M$16.2M$18.3M
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$35.5M$27M
Total non-current assets$14.1M$52M$45.6M
Total assets$330.6M$441.9M$444.1M
Accounts payable$3.11M$3.79M$2.42M
Short-term debt$2.08M$1.93M$1.78M
Deferred revenue$0.00$0.00$0.00
Total current liabilities$31M$36.2M$18.2M
Long-term debt$12M$14.1M$16M
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$12M$14.1M$16M
Capital lease obligations$14.1M$16M$17.8M
Total liabilities$43.1M$50.3M$34.3M
Common stock$287.5M$391.3M$410.7M
Retained earnings$0.00$0.00$0.00
Accumulated other comprehensive income (loss)-$-20K$300K-$-800K
Total equity$287.5M$391.6M$409.9M
Total investments$73.4M$297.8M$382M
Total debt$14.1M$16M$17.8M
Net debt-$-224.08M-$-107.04M-$-18.15M
Cash flow statement
202520242023
Net income-$-166.09M-$-163.71M-$-106.15M
Depreciation and amortization$2.42M$2.4M$2.38M
Stock-based compensation$32.3M$26.8M$18.4M
Change in working capital-$-1.52M$19M$2.9M
Accounts receivable$0.00$0.00$0.00
Inventory$0.00$0.00$0.00
Accounts payable$0.00$17.8M$8.39M
Net cash provided by operating activities-$-142.93M-$-125.81M-$-93M
Investments in property, plant and equipment-$-90K-$-360K-$-810K
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities$228M$95.4M$144.8M
Common stock issued$0.00$117.5M$0.00
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$30M$117.5M-$-87.09M
Net change in cash$115.1M$87.1M-$-35.34M
Cash at end of period$238.2M$123.1M$36M
Operating cash flow-$-142.93M-$-125.81M-$-93M
Capital expenditure-$-90K-$-360K-$-810K
Free cash flow-$-143.01M-$-126.16M-$-93.81M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About First Tracks Biotherapeutics Inc

        First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

        CEO
        Daniel R. Faga
        Employees
        104
        Beta
        3.37

        Explore

        Frequently asked questions

        What is the intrinsic value of First Tracks Biotherapeutics Inc (TRAX)?

        InvestorsCraft does not currently publish an intrinsic value for TRAX. How the IC value is calculated.

        Is TRAX undervalued?

        InvestorsCraft does not publish an undervaluation signal for TRAX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.